Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetics of response to proton pump inhibitor therapy: clinical implications.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice - 1 Jan 2003

Dickson Euan J, Stuart Robert C

Abstract excerpt

Proton pump inhibitors (PPIs) are highly effective agents for the treatment of gastric acid-related disorders. They are metabolized by the cytochrome P450 (CYP) system, mainly via the enzyme CYP2C19. A genetically determined defect in this pathway results in impaired metabolism of PPIs, giving rise to three distinct phenotypes: rapid extensive (fast), extensive (medium), and poor (slow) metabolizers. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Diseases

Share to Genetic Variation

Share to Mixed Function Oxygenases

Share to Proton Pump Inhibitors

Share to Proton Pumps

Source

Identifiers

PMID: 14575519
DOI: 10.2165/00129785-200303050-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetics of response to proton pump inhibitor therapy: clinical implications.PMID 14575519Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.Semantic proximity Read ↗

Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.